STX18-AS1: A Potential Drug Target and Biomarker (G100507266)

Target Name: STX18-AS1

NCBI ID: G100507266

STX18-AS1

Other Name(s): STX18 antisense RNA 1 (head to head)

STX18-AS1: A Potential Drug Target and Biomarker

Staurolactone (STX) is a steroid hormone that plays a crucial role in the development and maintenance of bone and cartilage health. It is produced by the adrenal gland and has been shown to have a wide range of physiological and therapeutic effects. One of the unique aspects of STX is its ability to cross the blood-brain barrier, which allows it to influence tissues and cells that are normally inaccessible. This property makes STX an attractive drug target and a potential biomarker for various diseases.

STX18-AS1: A Potential Drug Target

The protein STX18-AS1 is a potential drug target for various diseases, including cancer, neurodegenerative diseases, and autoimmune disorders. It is a key regulator of the cell cycle and has been shown to play a role in the development and progression of various diseases.

One of the key functions of STX18-AS1 is its role in the regulation of cell division. It is a co-factor of the cyclin D1-STX18-AS1 complex, which is responsible for regulating the G1 phase of the cell cycle. The G1 phase is a critical time for cell growth and development, and STX18-AS1 plays a role in ensuring that cells enter the G1 phase at the correct time and that the cell cycle proceeds smoothly.

In addition to its role in cell division, STX18-AS1 has also been shown to be involved in the regulation of cell adhesion and migration. It is a co-factor of the protein Trafficking in Organisms withMembranes (TIM), which is involved in the regulation of cell-cell and cell-tissue interactions. This suggests that STX18-AS1 may be involved in the development and maintenance of various diseases, including cancer.

STX18-AS1 as a Biomarker

The ability of STX18-AS1 to cross the blood-brain barrier and its role in the regulation of cell division, cell adhesion, and migration make it an attractive biomarker for various diseases. One of the key advantages of using STX18-AS1 as a biomarker is its ability to provide information about the underlying biological processes that are causing a disease. This information can be used to develop new treatments and to identify potential drug targets.

For example, if STX18-AS1 is shown to be involved in the regulation of cell division, it may be a potential drug target for diseases that are characterized by abnormal cell division, such as cancer. If STX18-AS1 is involved in the regulation of cell adhesion and migration, it may be a potential biomarker for diseases that are characterized by the disruption of these processes, such as neurodegenerative diseases.

Conclusion

In conclusion, STX18-AS1 is a potential drug target and biomarker for various diseases. Its ability to cross the blood-brain barrier and its role in the regulation of cell division, cell adhesion, and migration make it an attractive candidate for drug development. Further research is needed to fully understand the role of STX18-AS1 in various diseases and to develop new treatments based on this information.

Protein Name: STX18 Antisense RNA 1 (head To Head)

The "STX18-AS1 Target / Biomarker Review Report" is a customizable review of hundreds up to thousends of related scientific research literature by AI technology, covering specific information about STX18-AS1 comprehensively, including but not limited to:
•   general information;
•   protein structure and compound binding;
•   protein biological mechanisms;
•   its importance;
•   the target screening and validation;
•   expression level;
•   disease relevance;
•   drug resistance;
•   related combination drugs;
•   pharmacochemistry experiments;
•   related patent analysis;
•   advantages and risks of development, etc.
The report is helpful for project application, drug molecule design, research progress updates, publication of research papers, patent applications, etc. If you are interested to get a full version of this report, please feel free to contact us at BD@silexon.ai

More Common Targets